SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is driving intense community engagement through its multichain presence and deflationary burn mechanism, with supporters actively building a cult-like following. Investors are heavily focused on the project's long-term potential, frequently encouraging others to increase their positions while highlighting the meme's unique brand identity.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending as investors react to a significant executive order accelerating research pathways for psychedelic-based therapies, which has bolstered confidence in the sector's regulatory outlook. The community is actively discussing the potential for institutional re-rating, strong cash reserves, and upcoming Phase 3 trial data, with many debating the company's status as a top buyout candidate.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as investors highlight its fundamental strength and consistent revenue generation compared to other DeFi protocols. The community remains focused on long-term accumulation, closely monitoring technical support levels and broader market volatility as traders debate the project's potential for future growth.

Highstreet

Highstreet is seeing intense community debate and speculative trading as users analyze its potential for a short squeeze following a significant pullback from previous highs. Discussions are heavily polarized, with many traders debating the risk of further declines against the potential for a rapid technical reversal based on low supply and oversold indicators.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a long-awaited breakout, driven by its cybersecurity utility and low market cap. Discussion is currently dominated by bullish sentiment regarding the token's potential for explosive gains, whale accumulation patterns, and hopes for upcoming catalysts that could trigger a significant price reversal.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant volatility and heightened investor interest as the market reacts to a major rebrand and leadership changes, while simultaneously tracking key clinical catalysts including Phase 2 readouts for its anxiety pipeline and Phase 3 progress for its lead depression program. Community discussions are deeply polarized, with some investors focusing on the company's strong patent portfolio and potential for a sector-wide regulatory re-rating, while others remain skeptical due to historical dilution, poor stock performance, and the company's rebranding efforts.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as market sentiment surges following news of the company's progress toward late-stage clinical trials for PTSD and an accelerated timeline for treatment-resistant depression commercialization. The community is actively discussing the stock's potential for FDA approval and future M&A activity, with retail sentiment buoyed by the prospect of policy tailwinds in the psychedelic-assisted therapy sector.

SAP SE engages in the provision of enterprise application software and software-related services. It operates through the following segments: Applications, Technology, and Support; Qualtrics; and Services. The Applications, Technology, and Services segment includes sale of software licenses, support offerings, and cloud subscriptions. The Qualtrics segment sells experience management cloud solutions. The Services segment offers professional services, premium support services, implementation services for software products, and education services on the use of products. The company was founded by Hasso Plattner, Klaus Tschira, Claus Wellenreuther, Dietmar Hopp, and Hans-Werner Hector on April 1, 1972 and is headquartered in Walldorf, Germany.

Sap SE - ADR

SAP AG

SAP is facing significant market volatility as investors debate the impact of AI on the software sector, with community discussion split between those wary of AI disruption to traditional ERP models and those bullish on the company's cloud-driven AI integration. Sentiment is currently heavily influenced by institutional positioning, share repurchase announcements, and ongoing concerns regarding sector-wide software valuation.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently trending due to intense frustration from presale investors reporting significant difficulties with wallet connections, token claims, and widespread allegations that the project is an elaborate exit scam. While some community members continue to promote the network's mining app and potential future utility, a growing number of participants are warning others to avoid the project, citing non-functional support, missing assets, and concerns over deceptive marketing tactics.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors weigh its potential for recovery, with the community actively debating the impact of its recent institutional partnerships and integration within the ASI Alliance. While some traders express frustration over recent price volatility, others are focused on long-term accumulation, citing the project's role in the growing autonomous AI agent infrastructure as a key driver for future momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CAAS Company said in Q3 they expect to have revenue of 730M for the full year. I believe they will come with a massive beat. 745M is more like it. I think they will have a Q4 revenue that is above 200M. A growth company that is profitable with a PE at 3.8 is simply ridiculous.

StockTwits Web

China Automotive Systems Inc

 Company said in Q3 they expect to have revenue of 730M for the full year. I believe they will come with a massive beat. 745M is more like it. I think they will have a Q4 revenue that is above 200M. A growth company that is profitable with a PE at 3.8 is simply ridiculous.